PD Guide

PARK13 (Omi/HtrA2)

PARK13, PRSS25, OMI, HTRA2

PARK13 was identified as a possible susceptibility factor through candidate gene studies of Omi/HtrA2, a mitochondrial, antiapoptotic serine protease (Strauss et al., 2005; Bogaerts et al., 2008). Mutations in the gene were reported to affect the protease function of Omi/HtrA2 resulting in possible mitochondrial dysfunction (Strauss et al., 2005). Omi/HtrA1 has also been suggested to be modulated by PINK1 (Plun-Favreau et al., 2007). However, despite initial findings, further studies have not widely confirmed the initial association of Omi/HtrA2 mutations to PD (Simón-Sánchez et al., 2008; Ross et al., 2008).